News Mixed results for experimental Alzheimer's therapies at CTAD The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
News Eisai's full lecanemab phase 3 trial results for Alzheimer's... Following the news of two lecanemab-related deaths reported on the eve of the C
News Mixed results for experimental Alzheimer's therapies at CTAD The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.